November 1, 2023 QuidelOrtho 2023 Third Quarter 2023 Financial Results Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial, regulatory and other strategic goals, financial ...

Forward-Looking Statements QuidelOrtho Financial Results 2Q 2023 Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include any statements contained herein that are not strictly historical, including, but not limited to, the synergies and other benefits and results of the business combination (the "Combinations") of Quidel C ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2023 Earnings Call August 8, 2023 5:00 PM ET Company Participants Bryan Brokmeier - Vice President of Investor Relations Douglas C. Bryant - President and Chief Executive Officer Joseph M. Busky - Chief Financial Officer Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Jack Meehan - Nephron Research Casey Woodring - JPMorgan Operator Welcome to the QuidelOrtho Second Quarter 2023 Financial Results Conference Call and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-Q ____________________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended April 2, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Co ...

In terms of capital deployment in the first quarter, we paid down $52 million of debt working towards the $206 million minimum payments in 2023. And while we did not buy back any shares in the quarter, we intend to maintain a balanced and opportunistic approach to share repurchases while also continuing to prioritize our debt paydown going forward. Notably, following the end of the quarter, we made our final $40 million payment to Abbott for the $680 million purchase of the Alere cardiometabolic assets. We ...

• Non-respiratory revenue up 7% y/y on a supplemental combined basis QuidelOrtho – Proprietary & Confidential. | © 2023. All Rights Reserved. 8 • China strength was driven by the end of lockdowns Non-GAAP Financial Measures: This presentation contains financial measures, including but not limited to "constant currency" revenue changes, "adjusted net income," "adjusted diluted EPS," "adjusted EBITDA," "adjusted EBITDA margin," "supplemental combined adjusted net income," "supplemental combined adjusted dilut ...

February 15, 2023 QuidelOrtho Financial Results 4Q & FY 2022 © 2023. All Rights Reserved. 2 Forward-Looking Statements Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements in this presentation by words such as "may," "will," "would," "expect," "anticipate," "believe," "estimate," "plan," "intend," "continue" o ...

Andrew Brackmann Yeah. Hey, Andrew. We did go -- the $300 million to $500 million is still our range. So thatÂ's consistent and we can talk about the government contracts. But thatÂ's -- we are not treating that as normal and usual. [Inaudible] Joe Busky Hey, guys. Thank you for taking the questions. Hey, guys. Thanks for taking the question. I appreciate it. Yeah. Thanks, Conor. Joe Busky Oh! Eliza. Doug Bryant Okay. Makes total sense. And then I just wanted to get some clarification around the EBITDA to f ...

QuidelOrtho Corporation (NASDAQ:QDEL) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Douglas Bryant - Chairman and CEO Joseph Busky - CFO Conference Call Participants Andrew Cooper - Raymond James Patrick Donnelly - Citi Andrew Brackmann - William Blair Alexander Nowak - Craig Hallum Casey Woodring - JP Morgan Operator Welcome to the QuidelOrtho Third Quarter 2022 Financial Results Conference Call and Webcast. At this ti ...